Relative to AD 3,3 the levels of IL-1β protein in AD 4,4 carriers were 2.41-fold higher (p-0.005), which showed 1.38-fold increased expression compared to AMC homogenates (Figure 1D,E). This evidence concerns the gene IL1B and Alzheimer disease.